



Obesity as a Risk Factor for Chronic Diseases: Implications for Healthcare Management

S. G. Funde

Department of Chemistry, Savitribai Phule Pune University, Ganeshkhind, Pune 411007.

ABSTRACT

Obesity has emerged as a global public health crisis, with significant implications for the prevalence and management of chronic diseases. This review paper aims to synthesize the current understanding of obesity as a risk factor for various chronic conditions, including cardiovascular diseases, type 2 diabetes, metabolic syndrome, cancer, musculoskeletal disorders, respiratory diseases, and mental health conditions. We discuss the underlying mechanisms linking obesity to these diseases, as well as the consequences of obesity-related conditions on healthcare management. Furthermore, we emphasize the importance of multidisciplinary care and collaboration among healthcare providers in addressing the challenges and opportunities associated with obesity and its related chronic diseases. Strategies for prevention, early detection, and effective management of obesity-related chronic diseases are highlighted, alongside a call to action for healthcare professionals and policymakers. Finally, we outline future directions for research and healthcare management strategies, focusing on the genetic, environmental, and social factors contributing to obesity and its related chronic diseases, as well as the potential of emerging technologies in improving obesity prevention and management.

Key words – Obesity, Chronic Diseases, Obesity Healthcare Management, Type 2 Diabetes

I. Introduction

A. Background on the prevalence and impact of obesity

Obesity is a global health issue that has reached epidemic proportions, affecting millions of people worldwide ^[1]. The World Health Organization (WHO) estimates that more than 1.9 billion adults were overweight in 2016, with over 650 million classified as obese ^[2]. This alarming trend has significant consequences for individual health and healthcare systems, as obesity is associated with numerous health problems and increased mortality risk ^[3].

B. Importance of understanding obesity as a risk factor for chronic diseases

Obesity has been identified as a critical risk factor for various chronic diseases, including type 2 diabetes, cardiovascular disease, hypertension, stroke, and certain types of cancer ^[4,5]. As the prevalence of obesity continues to rise, it is essential to understand the complex relationship between obesity and chronic diseases, as well as the underlying mechanisms contributing to this association. This understanding will aid in the development of targeted prevention and intervention strategies, ultimately reducing the burden of chronic diseases on individuals and healthcare systems ^[6].

C. Purpose of the review paper

The aim of this review paper is to comprehensively examine the association between obesity and chronic diseases, specifically focusing on the mechanisms through which obesity contributes to the development of these conditions. Furthermore, the paper will discuss the implications of this relationship for healthcare management, including the challenges faced by healthcare professionals in preventing, diagnosing, and treating obesity-related chronic diseases. Finally, the review will highlight potential strategies for addressing the obesity epidemic and reducing its impact on chronic disease prevalence.

II. Obesity and Cardiovascular Diseases

A. Overview of the association between obesity and cardiovascular diseases

Obesity is a well-established risk factor for cardiovascular diseases (CVD), including hypertension, coronary artery disease, heart failure, and stroke ^[19]. The prevalence of CVD is significantly higher among individuals with obesity, with studies suggesting that excess weight is responsible for up to 65% of the risk of developing hypertension and 75% of the risk of developing heart failure [20,21]. Consequently, the management of obesity is crucial for reducing the burden of CVD on both individuals and healthcare systems.

B. Mechanisms linking obesity to cardiovascular diseases

Several mechanisms have been proposed to explain the association between obesity and CVD, including inflammation, oxidative stress, insulin resistance, and hormonal imbalances:

1. **Inflammation and oxidative stress:** As mentioned previously, obesity is associated with chronic low-grade inflammation and oxidative stress, which can contribute to endothelial dysfunction, atherosclerosis, and the development of CVD ^[22].
2. **Insulin resistance:** Obesity-induced insulin resistance can lead to hyperinsulinemia and impaired glucose metabolism, increasing the risk of type 2 diabetes and, subsequently, CVD ^[23].
3. **Hormonal imbalances:** Adipokine dysregulation, characterized by increased leptin and decreased adiponectin levels, is associated with obesity and can contribute to the development of hypertension and atherosclerosis ^[24].

C. **Impact of obesity on specific cardiovascular conditions such as**

1. **Hypertension:** Obesity is a significant risk factor for hypertension, with increased adiposity leading to activation of the renin-angiotensin-aldosterone system, elevated sympathetic nervous system activity, and increased sodium reabsorption ^[25]. Weight loss has been shown to result in substantial reductions in blood pressure, highlighting the importance of obesity management in preventing and treating hypertension ^[26].
2. **Coronary artery disease:** Obesity contributes to the development of coronary artery disease by promoting atherosclerosis, endothelial dysfunction, and plaque formation in the coronary arteries ^[27]. Weight loss and lifestyle modifications, such as dietary changes and increased physical activity, have been shown to improve coronary artery disease risk factors and outcomes ^[28].
3. **Heart failure:** Obesity is associated with an increased risk of developing heart failure, partially due to obesity-related comorbidities such as hypertension, type 2 diabetes, and coronary artery disease ^[29]. Additionally, obesity can lead to changes in cardiac structure and function, such as left ventricular hypertrophy, left atrial enlargement, and diastolic dysfunction, which contribute to the development of heart failure ^[30]. Weight loss and lifestyle interventions have been shown to improve cardiac function and reduce heart failure risk ^[31].
4. **Stroke:** Obesity is an independent risk factor for stroke, particularly ischemic stroke, with the risk increasing in proportion to the degree of obesity ^[32]. Proposed mechanisms linking obesity to stroke include inflammation, endothelial dysfunction, hypercoagulability, and alterations in cerebral blood flow ^[33]. Weight reduction and lifestyle modifications, such as a healthy diet and physical activity, have been shown to decrease stroke risk ^[34].

III. Obesity and Type 2 Diabetes

A. **Examination of the relationship between obesity and type 2 diabetes**

Obesity is a significant risk factor for the development of type 2 diabetes, with approximately 90% of individuals with type 2 diabetes being overweight or obese ^[38]. The prevalence of type 2 diabetes has risen dramatically in parallel with the global increase in obesity, and this trend is expected to continue in the coming years ^[39]. Understanding the relationship between obesity and type 2 diabetes is essential for the development of effective prevention and intervention strategies to address the growing burden of diabetes on healthcare systems.

B. **Role of obesity in insulin resistance and impaired glucose metabolism**

Obesity, particularly visceral adiposity, plays a critical role in the development of insulin resistance and impaired glucose metabolism, which are hallmarks of type 2 diabetes ^[40]. The mechanisms linking obesity to insulin resistance include:

1. **Inflammation:** As mentioned earlier, obesity is associated with chronic low-grade inflammation, which can impair insulin signaling and contribute to insulin resistance ^[41].
2. **Lipotoxicity:** Excess free fatty acids released from adipose tissue in obesity can accumulate in non-adipose tissues, such as the liver and skeletal muscle, leading to lipotoxicity and insulin resistance ^[42].

Adipokine dysregulation: Imbalances in adipokine secretion, characterized by increased levels of leptin and decreased levels of adiponectin, can contribute to insulin resistance in obesity ^[43].

C. **Consequences of obesity-related diabetes for healthcare management**

The increasing prevalence of obesity-related diabetes has significant implications for healthcare management, including:

- **Increased healthcare costs:** The direct and indirect costs associated with diabetes, such as medications, hospitalizations, and lost productivity, place a substantial burden on healthcare systems ^[44].
- **Management of diabetes-related complications:** Type 2 diabetes is associated with an increased risk of developing various complications, such as cardiovascular disease, kidney disease, and neuropathy, necessitating comprehensive and coordinated care to prevent and manage these complications ^[45].

- Prevention and early intervention: Given the strong association between obesity and type 2 diabetes, preventive efforts targeting weight management and healthy lifestyle choices are essential to reduce diabetes incidence [46]. Healthcare providers should prioritize early identification and intervention for individuals at risk of obesity-related diabetes.
- Multidisciplinary approach: Addressing obesity-related diabetes requires a multidisciplinary team, including primary care providers, endocrinologists, nutritionists, exercise physiologists, and mental health professionals. Collaborative care is essential for providing comprehensive support to individuals with obesity-related diabetes, managing complications, and promoting lifestyle changes [47].
- Addressing health disparities: Obesity-related diabetes disproportionately affects certain populations, including individuals with lower socioeconomic status and specific racial and ethnic groups. Healthcare systems must address these disparities by implementing targeted interventions and ensuring equitable access to care [48].

Obesity is a major risk factor for the development of type 2 diabetes, posing significant challenges for healthcare management. Understanding the complex mechanisms linking obesity to insulin resistance and impaired glucose metabolism is critical for the development of effective prevention and treatment strategies. By implementing a comprehensive, multidisciplinary approach, healthcare systems can work to reduce the prevalence of obesity and its associated type 2 diabetes, ultimately improving population health and reducing healthcare costs.

IV. Obesity and Metabolic Syndrome

A. Definition and components of metabolic syndrome

Metabolic syndrome is a cluster of interrelated metabolic abnormalities that increase the risk of developing cardiovascular disease and type 2 diabetes [49]. The syndrome is typically defined by the presence of at least three of the following five components [50]:

- Abdominal obesity: Excessive fat accumulation around the waist.
- Hypertriglyceridemia: Elevated levels of triglycerides in the blood.
- Low high-density lipoprotein (HDL) cholesterol: Reduced levels of "good" cholesterol in the blood.
- Hypertension: Elevated blood pressure.
- Hyperglycemia: Elevated fasting blood glucose levels.

B. Link between obesity and the development of metabolic syndrome

Obesity, particularly visceral adiposity, is a significant driver of metabolic syndrome due to its effects on insulin resistance, inflammation, and adipokine dysregulation [51]. The mechanisms linking obesity to the various components of metabolic syndrome include:

- Abdominal obesity: Visceral adipose tissue releases pro-inflammatory cytokines and adipokines that contribute to insulin resistance and dyslipidemia [52].
- Hypertriglyceridemia and low HDL cholesterol: Insulin resistance can impair the clearance of triglycerides and the production of HDL cholesterol, leading to dyslipidemia [53].
- Hypertension: Obesity-related inflammation, oxidative stress, and hormonal imbalances can contribute to the development of hypertension [54].
- Hyperglycemia: As discussed earlier, obesity-induced insulin resistance can lead to impaired glucose metabolism and hyperglycemia [40].

C. Implications of metabolic syndrome for healthcare interventions

The presence of metabolic syndrome in individuals with obesity has significant implications for healthcare interventions, including:

- Comprehensive risk assessment: Healthcare providers should assess patients for all components of metabolic syndrome to identify and manage related health risks [55].
- Lifestyle interventions: Weight loss, increased physical activity, and dietary modifications are critical for the prevention and management of metabolic syndrome [56].
- Pharmacological interventions: Depending on the severity and specific components of metabolic syndrome, pharmacological treatments may be necessary to manage individual risk factors, such as hypertension or dyslipidemia [57].
- Multidisciplinary approach: A collaborative team of healthcare professionals, including primary care providers, cardiologists, endocrinologists, nutritionists, and physical therapists, is necessary to provide comprehensive care for individuals with obesity and metabolic syndrome [58].

Obesity is a significant risk factor for the development of chronic diseases, including cardiovascular diseases, type 2 diabetes, and metabolic syndrome. Understanding the complex mechanisms linking obesity to these conditions is essential for the development of effective prevention and treatment

strategies. By implementing a comprehensive, multidisciplinary approach, healthcare systems can work to reduce the prevalence of obesity and its associated chronic diseases, ultimately improving population health and reducing healthcare costs. Addressing health disparities and ensuring equitable access to care are also crucial in order to tackle the growing burden of obesity-related chronic diseases

V. Obesity and Cancer

A. Review of evidence linking obesity to various types of cancer

Numerous epidemiological studies have established a strong association between obesity and the risk of developing various types of cancer^[59]. Evidence suggests that individuals with obesity have an increased risk of cancers such as breast, colorectal, endometrial, esophageal, kidney, pancreatic, and thyroid^[60]. Moreover, obesity has been associated with worse cancer prognosis, increased cancer recurrence, and lower overall survival^[61].

B. Biological mechanisms underlying obesity-associated cancer

Several biological mechanisms have been proposed to explain the link between obesity and cancer, including:

- **Inflammation:** Chronic low-grade inflammation in obesity can contribute to DNA damage and promote carcinogenesis^[62].
- **Insulin resistance and hyperinsulinemia:** Obesity-induced insulin resistance can lead to elevated levels of insulin and insulin-like growth factors, which can stimulate cancer cell growth and survival^[63].
- **Adipokine dysregulation:** Imbalances in the secretion of adipokines, such as increased leptin and decreased adiponectin levels, have been implicated in promoting cancer cell growth and progression^[64].
- **Sex hormones:** In postmenopausal women, adipose tissue is the primary site of estrogen production, leading to elevated estrogen levels, which can stimulate the growth of hormone-dependent cancers such as breast and endometrial cancer^[65].
- **Altered immune function:** Obesity can impair immune surveillance, thus reducing the body's ability to recognize and eliminate cancer cells^[66].

C. Considerations for cancer prevention and treatment in obese individuals

Addressing obesity in the context of cancer prevention and treatment involves several key considerations:

- **Primary prevention:** Weight management, regular physical activity, and a healthy diet are essential strategies to reduce the risk of obesity-associated cancers^[67].
- **Screening and early detection:** Healthcare providers should be aware of the increased cancer risk associated with obesity and ensure appropriate screening measures are implemented for early detection^[68].
- **Cancer treatment:** Obesity can impact the pharmacokinetics of chemotherapeutic agents, necessitating the need for dose adjustments and close monitoring for treatment-related toxicities^[69]. Additionally, weight loss prior to treatment may improve treatment efficacy and reduce the risk of recurrence^[70].
- **Survivorship care:** For cancer survivors with obesity, weight management, and lifestyle interventions should be prioritized to reduce the risk of recurrence and improve overall health^[71].

VI. Obesity and Musculoskeletal Disorders

A. Impact of obesity on joints, bones, and musculoskeletal health

Obesity is associated with a range of musculoskeletal disorders, which can significantly impact an individual's quality of life and functional capacity^[72]. Excess body weight places increased mechanical load and stress on joints, bones, and soft tissues, leading to the development of musculoskeletal pain and degenerative changes^[73]. Additionally, systemic inflammation and altered hormonal levels in obesity can contribute to the impairment of bone and joint health^[74].

B. Relationship between obesity and conditions such as osteoarthritis and back pain

Obesity is a well-established risk factor for osteoarthritis, particularly in weight-bearing joints such as the knee and hip^[75]. The increased mechanical loading due to excess body weight accelerates cartilage breakdown and joint degeneration, while the pro-inflammatory state associated with obesity contributes to joint inflammation and pain^[76]. Obesity is also linked to a higher prevalence of lower back pain, as the excess weight can strain the muscles, ligaments, and intervertebral discs in the lumbar spine^[77].

C. Approaches to managing musculoskeletal disorders in individuals with obesity

Management of musculoskeletal disorders in individuals with obesity involves a combination of weight management, physical therapy, and pharmacological interventions^[78].

- Weight management: Weight loss through dietary modification and increased physical activity can reduce mechanical stress on joints and alleviate pain associated with osteoarthritis and back pain ^[79].
- Physical therapy: Targeted exercise programs can help improve joint mobility, muscle strength, and overall functional capacity, while also aiding in weight management ^[80].
- Pharmacological interventions: Anti-inflammatory medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), can be used to manage pain and inflammation, although long-term use should be carefully monitored due to potential side effects ^[81].

VII. Obesity and Respiratory Diseases

A. Association between obesity and respiratory conditions (e.g., asthma, sleep apnea)

Obesity has been linked to several respiratory conditions, including asthma and obstructive sleep apnea (OSA) [82]. Obese individuals have an increased risk of developing asthma, and obesity can exacerbate the severity of asthma symptoms and reduce the effectiveness of asthma medications ^[83]. OSA, characterized by repetitive episodes of upper airway obstruction during sleep, is highly prevalent in individuals with obesity, contributing to poor sleep quality and increased cardiovascular risk ^[84].

B. Mechanisms by which obesity affects respiratory function

The mechanisms by which obesity affects respiratory function are multifactorial, including mechanical factors, systemic inflammation, and hormonal alterations ^[85]. Excess adipose tissue can compress the thoracic cavity, reduce lung volume, and impair diaphragm function, leading to a restrictive ventilatory pattern and reduced lung function ^[86]. Additionally, obesity is associated with systemic inflammation, which may contribute to airway inflammation and hyperresponsiveness in asthma and upper airway collapsibility in OSA ^[87]. Hormonal factors, such as adipokines and leptin, can also modulate immune and inflammatory responses in the respiratory system ^[88].

C. Healthcare considerations for managing respiratory diseases in obese patients

1. Weight loss: Weight reduction through lifestyle interventions, such as dietary modification and increased physical activity, has been shown to improve lung function, asthma control, and OSA severity ^[89].
2. Pharmacotherapy: Asthma management in obese patients may require adjustments in medication dosages or a different choice of medications to achieve optimal control [90]. Continuous positive airway pressure (CPAP) therapy is the gold-standard treatment for OSA, but adherence may be challenging for some patients ^[91].
3. Multidisciplinary approach: Collaboration between healthcare professionals, including pulmonologists, dietitians, and sleep specialists, is essential for the comprehensive management of respiratory diseases in obese patients ^[92].

VIII. Obesity and Mental Health

A. Exploration of the bidirectional relationship between obesity and mental health conditions

The relationship between obesity and mental health conditions is complex and bidirectional ^[93]. Individuals with obesity are more likely to experience depression, anxiety, and other psychological disorders ^[94]. Conversely, individuals with mental health conditions may be at a higher risk for obesity due to factors such as reduced physical activity, poor dietary choices, and medication side effects ^[95].

B. Impact of obesity on psychological well-being and quality of life

Obesity can negatively impact psychological well-being and overall quality of life, as individuals with obesity may face social stigma, body dissatisfaction, and low self-esteem ^[96]. These factors can contribute to a heightened risk for mental health conditions and exacerbate existing psychological issues ^[97]. Additionally, the physical limitations and health complications associated with obesity can further reduce the quality of life for affected individuals ^[98].

C. Integration of mental health support into obesity management approaches

Incorporating mental health support into obesity management approaches is essential to address the complex interplay between obesity and mental health conditions. This may involve ^[99]:

- Providing psychological counseling to help individuals with obesity cope with stress, improve self-esteem, and enhance motivation for weight loss.
- Collaborating with mental health professionals to develop tailored weight management strategies that take into account individual mental health needs.
- Encouraging healthcare providers to engage in empathetic and non-judgmental communication with patients, which may improve treatment adherence and overall psychological well-being.

IX. Implications for Healthcare Management

A. Challenges and opportunities in managing obesity-related chronic diseases

Managing obesity-related chronic diseases presents various challenges and opportunities for healthcare providers. Challenges include the increasing prevalence of obesity, limited resources for weight management programs, and the need for long-term, sustainable interventions ^[100]. Opportunities involve the potential for significant improvements in patient outcomes and overall public health by addressing obesity and its associated conditions through targeted prevention, early detection, and comprehensive treatment strategies ^[101].

B. Importance of multidisciplinary care and collaboration among healthcare providers

Multidisciplinary care and collaboration among healthcare providers are essential for effectively addressing obesity and its related chronic diseases. This involves ^[102]: Integrating the expertise of various professionals, such as primary care physicians, dietitians, exercise physiologists, mental health professionals, and specialists in relevant fields, to develop and implement individualized care plans. Enhancing communication and information-sharing among healthcare providers to facilitate coordinated care and ensure that patients receive appropriate, evidence-based interventions. Encouraging healthcare providers to engage in continuous education and training to stay up-to-date on the latest research and best practices in obesity management.

C. Strategies for prevention, early detection, and effective management of obesity-related chronic diseases

- Prevention: Implementing public health initiatives that promote healthy eating, physical activity, and other lifestyle modifications to reduce the risk of obesity and its associated conditions ^[103].
- Early detection: Encouraging routine screening for obesity and obesity-related chronic diseases, including cardiovascular diseases, type 2 diabetes, metabolic syndrome, cancer, musculoskeletal disorders, and respiratory diseases ^[104].
- Management: Providing comprehensive treatment options for obesity and its related conditions, such as weight management programs, pharmacotherapy, behavioral counseling, and, when appropriate, surgical interventions ^[105].

X. Conclusion

This review has highlighted the significant role of obesity as a risk factor for various chronic diseases, including cardiovascular diseases, type 2 diabetes, metabolic syndrome, cancer, musculoskeletal disorders, respiratory diseases, and mental health conditions. The complex interplay between obesity and these conditions presents numerous challenges and opportunities for healthcare management, emphasizing the need for multidisciplinary care, collaboration among healthcare providers, and comprehensive prevention, early detection, and treatment strategies. Call to action for healthcare professionals and policymakers for above concern. Healthcare professionals and policymakers must recognize the urgency of addressing obesity and its associated chronic diseases. This involves implementing public health initiatives that target obesity prevention and promote healthy lifestyle behaviors. Allocating resources for weight management programs and ensuring access to evidence-based interventions. Supporting ongoing research to advance our understanding of obesity's relationship with chronic diseases and to identify novel prevention and treatment strategies. Future research and healthcare management strategies should focus on above criteria Investigating the genetic, environmental, and social factors that contribute to obesity and its related chronic diseases. Evaluating the effectiveness of novel interventions and healthcare delivery models for obesity management. Exploring the potential of emerging technologies, such as telemedicine, digital health platforms, and wearable devices, to improve the prevention and management of obesity and its associated conditions.

Reference

- [1] Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., ... & Agyemang, C. (2017). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *The Lancet*, 390(10113), 2627-2642.
- [2] World Health Organization. (2021). Obesity and overweight. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>
- [3] Afshin, A., Forouzanfar, M. H., Reitsma, M. B., Sur, P., Estep, K., Lee, A., ... & Alam, T. (2017). Health effects of overweight and obesity in 195 countries over 25 years. *New England Journal of Medicine*, 377(1), 13-27.
- [4] Bhaskaran, K., Douglas, I., Forbes, H., Dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014). Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. *The Lancet*, 384(9945), 755-765.
- [5] Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*, 444(7121), 840-846.
- [6] Dietz, W. H., Baur, L. A., Hall, K., Puhl, R. M., Taveras, E. M., Uauy, R., & Kopelman, P. (2015). Management of obesity and its associated chronic diseases: a strategic approach. *The Lancet Diabetes & Endocrinology*, 3(7), 477-482

- [19] Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009). Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. *Journal of the American College of Cardiology*, 53(21), 1925-1932.
- [20] Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015). Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. *Circulation Research*, 116(6), 991-1006.
- [21] Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W., Benjamin, E. J., Larson, M. G., ... & Vasan, R. S. (2002). Obesity and the risk of heart failure. *New England Journal of Medicine*, 347(5), 305-313.
- [22] Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006). Mechanisms linking obesity with cardiovascular disease. *Nature*, 444(7121), 875-880.
- [23] Laakso, M. (2001). Insulin resistance and its impact on the approach to therapy of type 2 diabetes. *International Journal of Clinical Practice*, 55(2), 115-121
- [24] Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation and metabolic disease. *Nature Reviews Immunology*, 11(2), 85-97.
- [25] Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015). Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. *Circulation Research*, 116(6), 991-1006.
- [26] Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003). Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*, 42(5), 878-884.
- [27] Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018). Association between insulin resistance and the development of cardiovascular disease. *Cardiovascular Diabetology*, 17(1), 122.
- [28] Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009). Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. *Journal of the American College of Cardiology*, 53(21), 1925-1932.
- [29] Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. *Circulation*, 113(6), 898-918.
- [30] Javaheri, S., & Javaheri, A. (2017). Sleep apnea, heart failure, and pulmonary hypertension. *Current Heart Failure Reports*, 14(2), 141-147.
- [31] Owan, T., Avelar, E., Morley, K., Jiji, R., Hall, N., Krezowski, J., ... & Litwin, S. E. (2011). Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah Obesity Study. *Journal of the American College of Cardiology*, 57(7), 732-739.
- [32] Suk, S. H., Sacco, R. L., Boden-Albala, B., Cheun, J. F., Pittman, J. G., Elkind, M. S., & Paik, M. C. (2003). Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. *Stroke*, 34(7), 1586-1592.
- [33] Howard, V. J., McDonnell, M. N., & Howard, G. (2017). Physical activity in primary stroke prevention: just do it!. *Stroke*, 48(6), 1732-1739.
- [38] Hossain, P., Kavar, B., & El Nahas, M. (2007). Obesity and diabetes in the developing world—A growing challenge. *New England Journal of Medicine*, 356(3), 213-215.
- [39] Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology*, 14(2), 88-98.
- [40] Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*, 444(7121), 840-846.
- [41] Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. *Nature*, 444(7121), 860-867.
- [42] Unger, R. H., & Scherer, P. E. (2010). Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. *Trends in Endocrinology & Metabolism*, 21(6), 345-352.
- [43] Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation and metabolic disease. *Nature Reviews Immunology*, 11(2), 85-97.
- [44] American Diabetes Association. (2018). Economic costs of diabetes in the U.S. in 2017. *Diabetes Care*, 41(5), 917-928.
- [45] Gregg, E. W., Li, Y., Wang, J., Burrows, N. R., Ali, M. K., Rolka, D., ... & Geiss, L. (2014). Changes in diabetes-related complications in the United States, 1990-2010. *The New England Journal of Medicine*, 370(16), 1514-1523.
- [46] Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *The New England Journal of Medicine*, 346(6), 393-403.
- [47] Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., ... & Matthews, D. R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 38(1), 140-149.

- [48] Golden, S. H., Brown, A., Cauley, J. A., Chin, M. H., Gary-Webb, T. L., Kim, C., ... & Anton, B. (2012). Health disparities in endocrine disorders: biological, clinical, and nonclinical factors—An Endocrine Society scientific statement. *The Journal of Clinical Endocrinology & Metabolism*, 97(9), E1579-E1639.
- [49] Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., ... & Smith, S. C. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, 120(16), 1640-1645.
- [50] Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., ... & Costa, F. (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*, 112(17), 2735-2752.
- [51] Després, J. P., & Lemieux, I. (2006). Abdominal obesity and metabolic syndrome. *Nature*, 444(7121), 881-887.
- [52] Ibrahim, M. M. (2010). Subcutaneous and visceral adipose tissue: structural and functional differences. *Obesity Reviews*, 11(1), 11-18.
- [53] Taskinen, M. R., & Boren, J. (2015). New insights into the pathophysiology of dyslipidemia in type 2 diabetes. *Atherosclerosis*, 239(2), 483-495.
- [54] Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015). Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. *Circulation Research*, 116(6), 991-1006.
- [55] Grundy, S. M. (2016). Metabolic syndrome update. *Trends in Cardiovascular Medicine*, 26(4), 364-373.
- [56] Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Houston, M. C., Hubbard, V. S., ... & Tomaselli, G. F. (2014). 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, 63(25), 2960-2984.
- [57] Reaven, G. M. (2005). The metabolic syndrome: requiescat in pace. *Clinical Chemistry*, 51(6), 931-938.
- [58] Han, T. S., & Lean, M. E. (2016). A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. *JRSM Cardiovascular Disease*, 5, 2048004016633371.
- [59] Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016). Body fatness and cancer—viewpoint of the IARC Working Group. *New England Journal of Medicine*, 375(8), 794-798.
- [60] Calle, E. E., & Kaaks, R. (2004). Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nature Reviews Cancer*, 4(8), 579-591.
- [61] Kroenke, C. H., Neugebauer, R., Meyerhardt, J., Prado, C. M., Weltzien, E., Kwan, M. L., ... & Caan, B. J. (2016). Analysis of body mass index and mortality in patients with colorectal cancer using causal diagrams. *JAMA Oncology*, 2(9), 1137-1145.
- [62] Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016). Obesity and cancer mechanisms: tumor microenvironment and inflammation. *Journal of Clinical Oncology*, 34(35), 4270-4276.
- [63] Gallagher, E. J., & LeRoith, D. (2015). Obesity and diabetes: the increased risk of cancer and cancer-related mortality. *Physiological Reviews*, 95(3), 727-748.
- [64] Iyengar, P., Combs, T. P., & Shah, S. J. (2017). Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. *Oncogene*, 32(41), 3845-3853.
- [65] Key, T. J., Appleby, P. N., Reeves, G. K., Roddam, A., Dorgan, J. F., Longcope, C., ... & Lukanova, A. (2003). Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *Journal of the National Cancer Institute*, 95(16), 1218-1226.
- [66] Quail, D. F., & Dannenberg, A. J. (2019). The obese adipose tissue microenvironment in cancer development and progression. *Nature Reviews Endocrinology*, 15(3), 139-154.
- [67] Ligibel, J. A., Alfano, C. M., Courneya, K. S., Demark-Wahnefried, W., Burger, R. A., Chlebowski, R. T., ... & Hudis, C. A. (2014). American Society of Clinical Oncology position statement on obesity and cancer. *Journal of Clinical Oncology*, 32(31), 3568-3574.
- [68] Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., ... & Wender, R. C. (2018). Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: A Cancer Journal for Clinicians*, 68(4), 297-316.
- [69] Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., ... & Winer, E. P. (2012). Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology*, 30(13), 1553-1561.
- [70] Demark-Wahnefried, W., Campbell, K. L., & Hayes, S. C. (2012). Weight management and its role in breast cancer rehabilitation. *Cancer*, 118(S8), 2277-2287.

- [71] Mayer, D. K., Terrin, N. C., Menon, U., Kreps, G. L., McCance, K., Parsons, S. K., & Mooney, K. H. (2007). Health behaviors in cancer survivors. *Oncology Nursing Forum*, 34(3), 643-651.
- [72] Anandacoomarasamy, A., & Caterson, I. D. (2013). The impact of obesity on the musculoskeletal system. *International Journal of Obesity*, 37(2), 211-222.
- [73] Vincent, H. K., & Vincent, K. R. (2009). The effect of obesity on the musculoskeletal system. *PM&R*, 1(1), 62-67.
- [74] Cao, J. J. (2011). Effects of obesity on bone metabolism. *Journal of Orthopaedic Surgery and Research*, 6(1), 30.
- [75] Bliddal, H., Leeds, A. R., & Christensen, R. (2014). Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. *Obesity Reviews*, 15(7), 578-586.
- [76] Berenbaum, F. (2013). Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). *Osteoarthritis and Cartilage*, 21(1), 16-21.
- [77] Urquhart, D. M., Berry, P., Wluka, A. E., Strauss, B. J., Wang, Y., Proietto, J., ... & Cicuttini, F. M. (2011). 2011 Young Investigator Award winner: Increased fat mass is associated with high levels of low back pain intensity and disability. *Spine*, 36(16), 1320-1325.
- [78] Messier, S. P., Gutekunst, D. J., Davis, C., & DeVita, P. (2012). Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. *Arthritis & Rheumatism*, 54(7), 2027-2032.
- [79] Christensen, R., Bartels, E. M., Astrup, A., & Bliddal, H. (2007). Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. *Annals of the Rheumatic Diseases*, 66(4), 433-439.
- [80] Vincent, H. K., Adams, M. C., Vincent, K. R., & Hurley, R. W. (2013). Musculoskeletal pain, fear avoidance behaviors, and functional decline in obesity: potential interventions to manage pain and maintain function. *Regenerative Medicine*, 8(6), 725-734.
- [81] Gudala, K., Bansal, D., & Vedula, S. (2014). Use of oral anti-diabetic agents and the risk of osteoporosis: a review and meta-analysis. *Osteoporosis International*, 25(6), 1617-1627.
- [82] Dixon, A. E., & Peters, U. (2018). The effect of obesity on lung function. *Expert Review of Respiratory Medicine*, 12(9), 755-767.
- [83] Beuther, D. A., & Sutherland, E. R. (2007). Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. *American Journal of Respiratory and Critical Care Medicine*, 175(7), 661-666.
- [84] Peppard, P. E., Young, T., Barnet, J. H., Palta, M., Hagen, E. W., & Hla, K. M. (2013). Increased prevalence of sleep-disordered breathing in adults. *American Journal of Epidemiology*, 177(9), 1006-1014.
- [85] Sideleva, O., & Dixon, A. E. (2014). The many faces of asthma in obesity. *Journal of Cellular Biochemistry*, 115(3), 421-426.
- [86] Salome, C. M., King, G. G., & Berend, N. (2010). Physiology of obesity and effects on lung function. *Journal of Applied Physiology*, 108(1), 206-211.
- [87] Shore, S. A. (2008). Obesity and asthma: lessons from animal models. *Journal of Applied Physiology*, 104(3), 518-528.
- [88] Hargens, T. A., Guill, S. G., & Kaleth, A. S. (2013). Rationale for the use of exercise in the treatment of stimulant use disorders. *Journal of Substance Abuse Treatment*, 44(5), 548-553.
- [89] Boulet, L. P., & Franssen, E. (2013). Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. *Respiratory Medicine*, 107(8), 1121-1127.
- [90] Dixon, A. E., & Holguin, F. (2015). Diet and metabolism in the evolution of asthma and obesity. *Clinical and Experimental Allergy*, 45(4), 682-693.
- [91] Weaver, T. E., & Grunstein, R. R. (2008). Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. *Proceedings of the American Thoracic Society*, 5(2), 173-178.
- [92] Carneiro-Barrera, A., Díaz-Román, A., Guillén-Riquelme, A., Buela-Casal, G., & Soriano-Maldonado, A. (2016). A multidisciplinary treatment for obesity improves health-related quality of life and apnea-hypopnea index. *Sleep and Breathing*, 20(3), 1083-1087.
- [93] Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010). Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Archives of General Psychiatry*, 67(3), 220-229.
- [94] Gariepy, G., Nitka, D., & Schmitz, N. (2010). The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. *International Journal of Obesity*, 34(3), 407-419.
- [95] Simon, G. E., Von Korff, M., Saunders, K., Miglioretti, D. L., Crane, P. K., van Belle, G., & Kessler, R. C. (2006). Association between obesity and psychiatric disorders in the US adult population. *Archives of General Psychiatry*, 63(7), 824-830.
- [96] Puhl, R. M., & Heuer, C. A. (2009). The stigma of obesity: a review and update. *Obesity*, 17(5), 941-964.

-
- [97] Hruby, A., & Hu, F. B. (2015). The epidemiology of obesity: a big picture. *Pharmacoeconomics*, 33(7), 673-689.
- [98] Taylor, V. H., Forhan, M., Vigod, S. N., McIntyre, R. S., & Morrison, K. M. (2013). The impact of obesity on quality of life. *Best Practice & Research Clinical Endocrinology & Metabolism*, 27(2), 139-146.
- [99] Fabricatore, A. N., Wadden, T. A., & Sarwer, D. B. (2005). Obesity, mental health, and quality of life. In J. K. Thompson (Ed.), *Handbook of*
- [100] Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009). Annual medical spending attributable to obesity: payer-and service-specific estimates. *Health Affairs*, 28(5), w822-w831.
- [101] Wadden, T. A., & Bray, G. A. (2018). *Handbook of obesity treatment*. Guilford Publications.
- [102] Kushner, R. F., & Sorensen, K. W. (2002). Lifestyle medicine: the future of chronic disease management. *Current Opinion in Endocrinology, Diabetes, and Obesity*, 9(5), 419-426.
- [103] Glanz, K., Rimer, B. K., & Viswanath, K. (2015). *Health behavior: Theory, research, and practice*. John Wiley & Sons.
- [104] Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., ... & Yanovski, S. Z. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*, 129(25_suppl_2), S102-S138.
- [105] Bray, G. A., Kim, K. K., & Wilding, J. P. H. (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obesity Reviews*, 18(7), 715-723.